Shire’s angioedema drug succeeds in late-stage study

Image may be NSFW.
Clik here to view.Shire Plc said successful late-stage data on its long-acting drug for hereditary angioedema would form the basis of a U.S. marketing application for the treatment. U.S.-listed shares of company, which already sells a number of hereditary angioedema (HAE) treatments, were up about 6 percent at $193.15 before the bell on Thursday.